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Abstract
Background Unraveling the mechanisms of pain in chronic
pancreatitis (CP) remains a true challenge. The rapid develop-
ment of pancreatic surgery in the twentieth century, usage of
advanced molecular biological techniques, and emergence of
clinician-scientists have enabled the elucidation of several
mechanisms that lead to the chronic, complicated neuropathic
pain syndrome in CP. However, the proper analysis of pain in
CPshouldincludethreemainarmsofmechanisms:“peripheral
nociception,”“ peripheral/pancreatic neuropathy and neuro-
plasticity,” and “central neuropathy and neuroplasticity.”
Discussion According to our current knowledge, pain in
CP involves sustained sensitization of pancreatic peripheral
nociceptors by neurotransmitters and neurotrophic factors
following neural damage. This peripheral pancreatic neu-
ropathy leads to intrapancreatic neuroplastic alterations that
involve a profound switch in the autonomic innervation of
the human pancreas via “neural remodeling.” Furthermore,
this neuropathy entails a hyperexcitability of spinal sensory
second-order neurons, which are subject to modulation
from the brainstem via descending facilitation. Finally,
viscerosensory cortical areas react to this central sensitiza-
tion via spatial reorganization and thus a central neuro-
plasticity. The present review summarizes the current
findings in these arms of mechanisms and introduces a
novel concept to consistently describe pain in CP as a





Schmerz ist ein Meister, der uns klein macht,
Ein Feuer, das uns ärmer brennt,
Das uns vom eigenen Leben trennt,
Das uns umlodert und allein macht.
Pain is a master that renders us small,
A fire that burns us to vanity,
One that separates us from our own lives,
One that lights us up and makes us alone.
One of the major features of the poem above by the Swiss–
German Nobel laureate poet Hermann Hesse (1877–1962) is
the attribution of the trait of a “master” and a detrimental “fire”
to pain [1]. Indeed, there are probably no better words to
describe the eminence of pain in the lives of patients, a
problem that clinicians encounter daily in their clinical
practice. Regardless of its origin and the underlying disease,
chronic, enduring pain is a genuine challenge both to the
sufferer and the treating physicians. The poorly understood
mechanisms of pain generation and treatment reflect them-
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DOI 10.1007/s00423-010-0731-1selves even more in the context of pain originating from
visceral organs. If one had to pick a single visceral disorder
that literally reigns over the lives of the patients exactly the
same way as described by Hesse, then this would most likely
be the tormenting pain due to chronic pancreatitis (CP).
Reported by atleast 80–94% of patients with CP, chronic pain
due to CP is typically a burning, intermittent, and shooting
pain, often resulting in narcotic addiction [2, 3]. Advances in
molecular biology, enhanced access to human pancreatic
specimens owing to the increased emergence of “pancreatic
surgeons,” and the integration of pain specialists into
research and treatment related to this excruciating pain have
recently revealed numerous mechanisms that are thought to
spark it. In general, these mechanisms can be classified
according to their location or their relation to nerve damage.
Hence, one can differentiate between “peripheral” and
“central” mechanisms of pain in CP. However, what seems
to overhang these two is the classification into “nociceptive”
mechanisms, characterized by direct stimulation of intact
nerve fibers by the responsible agents, and into “neuropath-
ic” ones in the presence of nerve damage. This review
summarizes the current findings on pain in CP in three arms
of mechanisms (Fig. 1) and introduces a novel concept to
consistently describe pain in CP as neither solely nociceptive
nor only neuropathic, but rather as a “mixed-type” pain.
Peripheral nociceptive mechanisms: is there really
a direct activation?
In order to induce nociception, substances or noxi capable
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Fig. 1 Main actors in the
generation of pain in chronic
pancreatitis (CP). The neuro-





root ganglia/DRG, spinal cord,
brainstem, and cerebrum) sites.
The increased presence of
nociceptive signals in the
periphery as mediated by
neurotransmitters and neurotro-
phic factors is paralleled by
prominent neural damage and
numerous intrapancreatic neuro-
pathic/neuroplastic alterations.
At the same time, DRG and
spinal cord neurons exhibit a
hypersensitive state which is
subject to modulation from
the brainstem over descending
facilitation. Finally, the cerebral
cortex adapts to these caudal
alterations by increasing its
basal activity and changing its
spatial conformation in viscero-
sensory areas. Please refer to
the manuscript for further details
and the respective references
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the main gaps in our knowledge on pain mechanisms in CP
is that we still do not know what factors actually activate
the intrapancreatic nociceptors. Older studies originally
suggested ductal hypertension due to constriction or calculi,
increased intraparenchymal pressure as a result of fibrosis,
or toxic substances like alcohol as potential stimulators of
these receptors [4, 5]. However, none of these factors has
ever been proven to be directly associated with pancreatic
pain, and even in the absence of these factors, CP patients
are frequently victims of severe pain [4, 6–8]. Still, there
seems to be a peculiarity of alcohol-induced CP as opposed
to CP etiologies like biliary, idiopathic, and CP due to rare
etiologies (hereditary, etc.): In an unpublished study, we
analyzed the degree of pain among 211 patients with
different CP etiologies (Table 1). Obviously, patients with
alcohol-induced CP indeed had significantly (p<0.01)
higher degrees of pain than patients with CP due to other
etiologies (Table 1). As of today, there are no studies that
could provide a pathomechanistic explanation for this
clinical observation.
As CP is, in part, the result of recurrent attacks of acute
pancreatitis, substances that are thought to initiate acute
attacks of pancreatitis have also been the focus in terms of
their potential to trigger pain in CP. It has been suggested
that agents like protons, bradykinin, hydrogen sulfide,
serotonin, and calcium that are released after damage to
acinar cells result in activation of nociceptive fibers via
their respective receptors [9]. However, it is crucial to note
that the direct activation of nociceptive fibers due to these
molecules has never been demonstrated in any animal
model of CP or in human CP. Therefore, the activation of
nociceptive fibers via these molecules in CP is still a
theoretical assumption. In contrast, there are only two
nociceptive receptors that are found in the pancreas and
have been shown to be directly stimulated by such
substances: proteinase-activated receptor 2 (PAR-2) and
transient receptor potential vanilloid 1 (TRPV1; Fig. 1). In
their study, Hoogerwerf et al. showed that trypsin infusion
into the pancreatic duct of rats induces activation of sensory
dorsal root ganglia (DRG) neurons by binding to the PAR-2
as measured by their increased FOS immunoreactivity [10].
It should be noted that this study employed a behavioral
testing model instead of a CP model to demonstrate this
effect. In another important study, Xu et al. treated rats with
trinitrobenzene sulphonic acid (TNBS) to induce CP and
recorded significantly more depolarized resting potentials
and suppression of A-type potassium current density in
pancreas-specific DRG neurons than in controls [11]. This
evidence for the activation of nociceptive fibers was further
supported by the increased TRPV1 expression and
enhanced capsaicin responsiveness of pancreas-specific
DRG neurons in their CP model [11]. Furthermore, it is
also known that some of the inflammatory mediators stated
above can also indirectly activate TRPV1 by lowering its
activation threshold [12].
Due to the difficulties in identifying the direct activators of
nociceptive fibers in CP, what has become another means of
investigating the nociceptive mechanisms of pain in CP was
the assessment of nociceptive activation markers in CP. Once
activated, nociceptive nerve fibers secrete enhanced amounts
of neurotransmitters like glutamate, substance P, and
calcitonin gene-related peptide (CGRP) into the pancreas in
an anti-dromic fashion (Fig. 1). The release of these
mediators results in local inflammation due to the vaso-
dilatory and chemotactic effect of these mediators for
inflammatory cells. This concept of “neurogenic inflamma-
tion” as orchestrated by peripheral nociceptive fibers has
been thoroughly studied in experimental acute pancreatitis
[13, 14]. In CP, the involvement of neurogenic inflammation
is more difficult to prove, in part due to the short-lived action
of these neurotransmitters. However, Büchler et al. could
already show in a semi-quantitative analysis the upregulation
of SP- and CGRP-immunoreactive nerve fibers in human CP
specimens (Fig. 1)[ 15]. A subsequent study tried to verify
this finding by comparing the tissue levels of the SP-
expressing gene preprotachykinin A (PPT-A) in normal
pancreas (NP) and CP [16]. Strikingly, this study did not
detect any difference in terms of PPT-A expression in NP
and CP and therefore attributed the source of SP in CP to an
extrapancreatic location, e.g., to the DRG [16]. While the
exact role of SP in CP-associated nociception deserves
further investigation, another study demonstrated the upre-
gulation of its receptor neurokinin-1 (NK-1R) in nerves and
infiltrating inflammatory cells. Of importance, the expression
of NK-1R correlated with the intensity and frequency of
abdominal pain of CP patients [17].
Table 1 Pain degree in relation to chronic pancreatitis (CP) etiology
Etiology
of CP
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The individual pain score of 211 CP patients (i.e., pain intensity and
frequency) was prospectively registered prior to surgical resection. Pain
intensity was graded by using a short scale: 0=none, 1=mild, 2=
moderate, and 3=strong pain. Pain frequency was graded as 3=daily, 2=
weekly, and 1=monthly. To calculate the degree of pain, pain intensity
and pain frequency of each individual were multiplied. According to the
final pain score, the patients were divided into three groups: no pain (0),
mild pain (1–3), and moderate to severe pain (4–9)
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investigation is the vast family of neurotrophic factors. Of
these, nerve growth factor (NGF) has been the first suspect
in terms of nociception. Especially, NGF is known to
activate nociceptive nerve fibers and modulate SP expres-
sion via its high-affinity receptor TrkA and its low-affinity
receptor p75 [18]. We could previously demonstrate the
overexpression of NGF in CP tissue, mainly localized to
hypertrophic nerves, intrapancreatic ganglia, metaplastic
ductal cells, and degenerating acinar cells [19]. On the other
hand, while we detected no correlation between NGF
expression and pain sensation of CP patients, TrkA was
strongly expressed in the perineurium, and its mRNA
expression was strongly related to the degree of pain of CP
patients (Fig. 1)[ 19]. These findings on NGF ushered in a
subsequent study that demonstrated a similar upregulation
and pain correlation for the brain-derived neurotrophic
factor (BDNF) [20], which also exerts prominent nocicep-
tive effects by acting on the p75 receptor and the
sphingomyelin pathway [21]. These pioneering findings
demonstrating the role of neurotrophic factors in CP-related
peripheral nociception gained a novel dimension following
the analysis of the glial cell-line derived neurotrophic factor
(GDNF) family member artemin and its receptor GFRα3
(Fig. 1)[ 22]. It is known that artemin, especially in
conjunction with NGF, can induce hyperalgesia [23]. In
CP, both artemin and GFRα3 were significantly overex-
pressed, but interestingly, mainly located in Schwann cells,
intrapancreatic ganglia, and smooth muscle cells of arteries
(Fig. 1). While the amount of artemin expression by
nociceptive nerve fibers has not yet been quantified, there
is a strong correlation between its expression and the pain
severity. Hence, the activation of nociceptive/sensory DRG
neurons to produce artemin would lead to the retrograde
axonal transport of artemin in sensory afferents towards the
pancreas, as it is known for SP, CGRP, but also for other
GDNF family members [24]. The natural question that
arises out of this assumption is what effects neurotrophic
factors exert in pancreatic tissue. Due to their trophic
attributes, one can assume that they can induce the growth
of nerves or neural components. This assumption has
indeed been crucial for the understanding of “neuropathy”
in CP and helped to establish the link between nociception
and neuropathy in CP, as described below.
Peripheral neuropathic mechanisms: pancreatic
neuropathy as a prototype of visceral neuropathy
In order to understand “pancreatic neuropathy,” one should
carefully analyze the historical evolvement of this research
field. The motivation to investigate the above-mentioned
peripheral nociceptive mechanisms is in part derived from
parallel studies on acute pancreatitis. On the other hand, the
currently accepted notion of neuropathy in CP and other
pancreatic disorders has its roots in the initial recognition of
neural alterations in histopathological specimens. Keith et
al. for the first time reported prominent infiltration of
intrapancreatic nerves in CP by inflammatory cells and
especially eosinophils [25]. Strikingly, they found a major
correlation of pain with the percentage of eosinophilic
infiltration around these nerves [25]. In a subsequent
detailed study, Bockman et al. found out that nerves in
CP undergo an increase in their density and a hypertrophy.
However, what is even more important, they conducted an
ultrastructural analysis of intrapancreatic nerves in CP and
observed severe neural damage, as evidenced by disrupted
perineurium, edematous neural contents, and penetration of
inflammatory cells into the interior of nerves [4]. Unfortu-
nately, the importance of these observations remained
unrecognized until the advent of larger studies that
demonstrated a key correlation between the extent of neural
damage, neural sprouting, neural hypertrophy, the inflam-
mation around nerves (termed “pancreatic neuritis”), and
the pain frequency and intensity of CP patients [22, 26].
This fundamental correlation laid the foundation for the
increased realization of pancreatic neuropathy and neuro-
pathic pain in CP [22, 26] because neuropathic pain, as
suggested by the Neuropathic Pain Special Interest Group
of the International Association for the Study of Pain
(NeuPSIG), is defined as “pain arising as direct conse-
quence of a lesion or disease affecting the somatosensory
system” [27].
As pancreatic neuropathy increasingly drifted into the
attention of researchers, it resulted in the parallel
emergence of another cardinal concept, i.e., pancreatic
neuroplasticity. The damage to intrapancreatic nerves
indeed seems to be accompanied by numerous peripheral
neuroplastic changes, as best evidenced by the prominent
hypertrophy and sprouting of intrapancreatic nerves
(Fig. 1). Investigation of the well-established neural
plasticity marker growth-associated protein 43 (GAP-43)
in CP confirmed this phenomenon owing to its over-
expression in CP tissue [26, 28]. This plasticity gained a
further fascinating dimension after investigation of the
autonomic innervation of the pancreas in CP when
compared to NP [29]. When the sympathetic and para-
sympathetic innervations of the pancreas were compared
between CP and NP, there was a conspicuous decrease in
the pancreatic sympathetic innervation in CP. At first
glance, the parasympathetic innervation did not demon-
strate any major difference between CP and NP, but
importantly, both sympathetic and parasympathetic inner-
vations were even more severely diminished in CP
patients who suffered from severe neuropathic abdominal
pain and/or severe pancreatic neuritis [29].
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into consideration are not only the neuronal components
but also the state of the glia cells, i.e., Schwann cells, in
these nerves. The above-mentioned study aimed not only at
investigating the autonomic innervation in CP but also at
dissecting the role of Schwann cells in these altered nerves.
Glia cells are increasingly believed and shown to play a
pivotal role in neuropathic pain, especially due to inflam-
matory disorders [30]. In order to get an idea of their
activation state, we previously quantified the expression of
the glial transcription factor Sox10 and the neuroepithelial
stem cell marker Nestin in CP. In accordance with the
axioms of neuropathy, the activation state of glia in CP was
dramatically different: Intraneural Sox10 expression in CP
was extremely diminished, whereas there was a florid
increase in the intraneural Nestin immunoreactivity. These
findings helped to draw the first image of glia in pancreatic
neuropathy and are therefore of crucial significance. As a
response to nerve injury, Schwann cells start to proliferate,
undifferentiate, and promote axonal growth, remyelination,
and sensitization of nociceptors via release of neurotrophic
agents [30]. As Sox10 is continuously present in mature
Schwann cells [30, 31], decreased Sox10 expression in
nerves in CP is most likely an indicator of a reduction in the
number of mature Schwann cells, possibly due to the
above-mentioned reactive undifferentiation. This interpre-
tation is in line with the observed Nestin upregulation since
glial Nestin re-expression and subsequent neural sprouting
have been previously demonstrated after denervation of
muscles at the neuromuscular junction [32]. Therefore, the
alterations in Sox10 and Nestin in pancreatic neuropathy
are, although indirect, still clear indicators of glial activa-
tion (Fig. 1), as known for various neuropathies [33].
Overall, by looking at these neuropathic alterations in
CP involving three main axes, i.e., autonomic innervation
changes, glial activation, and associated neuropathic pain,
we can say that pancreatic neuropathy is characterized by a
“neural remodeling” [29, 34]. This profound alteration in
nerves supplying the pancreas may also be considered as a
factor in the dissatisfaction with results of pancreatic
“denervation” techniques that are used to treat pain in CP
[35]. Clinicians tend to believe that denervating the
pancreas, especially from the pain-transmitting fibers, can
be a therapeutic option. Until today, the denervation has so
far been undertaken at the level of celiac ganglion,
splanchnic nerves, or the pancreas itself [35]. Regarding
the techniques targeting at the celiac ganglion and splanch-
nic nerves, unfortunately, the overall success rate and
effectiveness of celiac plexus blockade (CPB), celiac plexus
neurolysis (CPN), and bilateral surgical trans-section of
splanchnic nerves (“bilateral splanchnicectomy”) remain
unsatisfactory. Although around 50% of the patients
experience major pain relief briefly after these interven-
tional procedures, the mean post-interventional pain-free
interval does not exceed 2–4 months, and lack of follow-up
after these 4 months is a common denominator of all these
studies. Furthermore, therapy failure is frequent in patients
with extensive peripancreatic fibrosis, and investigators
controversially defined pain relief as “no need for opioids”
[36–39]. Therefore, placebo-controlled, randomized clinical
trials are desperately needed to judge the true impact of
these interventions to treat pain in CP [34]. In fact, looking
at the neural remodeling in CP, these unsatisfying results
may not totally be a surprise. In particular, seeing the
prominent decrease in the amount of sympathetic nerve
fibers that run together with sensory fibers in splanchnic
nerves, one should ask about the distribution and amount of
sensory/nociceptive fibers in splanchnic and celiac plexus
nerves in CP patients. As previously suggested, it is
possible that pain in CP is transmitted via afferents other
than the ones running with splanchnic nerves, e.g., with
vagal or somatosensory afferents reaching the DRG [29,
35]. We are convinced that this anatomic remodeling may
be the underlying reason for the poor success of denerva-
tion procedures to treat pain in CP. However, it is also well
known that the most effective pain relief for CP patients
occurs following surgical resection of the pancreatic head
(e.g., duodenum-preserving pancreatic head resection and
classical pancreaticoduodenectomy), as proven by numerous
controlled trials [40–46]. Therefore, it is conceivable that
intervening at the origin of pancreatic neuropathy, i.e., the
intra-organ intervention, is more effective than surgical or
chemical ablation of nerve fibers, which may per se not be
the actual paths of pain transmission.
The interdependence between the extent of pancreatic
neuropathy, neural remodeling, and pancreatic neuritis
should also draw our attention once again to the role of
neuro-inflammation in the generation of this peripheral
visceral neuropathy. The actors that plot and produce
pancreatic neuritis are still unknown. From dozens
of known inflammation markers, it is only interleukin
8 (IL-8) which has been studied and shown to be overex-
pressed in CP tissues in comparison to NP, mainly
originating from inflammatory cells infiltrating hypertro-
phic nerves [16]. However, what factors attract inflamma-
tory cells to nerves and thereby mediate neural damage and
neuropathic pain? As an attempt to answer this key
question, we previously scrutinized neuron-derived chemo-
attractants, i.e., neuronal chemokines. The prototype for
such molecules is the chemokine fractalkine [47]. Fractal-
kine harbors three main attributes that turn it into a major
suspect to induce the above-describedneuropathicalterations
in CP: It is a chemoattractant for immune cells, induces
neuropathic pain via glial activation, and contributes to tissue
fibrosis [48–50]. In CP, we not only detected an over-
expression of tissue fractalkine and its receptor CX3CR1 on
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activity for fractalkine and CX3CR1 in patients suffering
from severe neuropathic pain and pancreatic neuritis [47].
Moreover, these alterations were even more pronounced
among patients who suffered from neuropathic pain for
already longer periods [47]. Thereby, we could for the first
time identify a molecular counterpart for the neuro-affinity of
inflammatory cells as induced by neuronal molecules. We are
convinced that blockade of CX3CR1 may be of substantial
benefit in terms of improvement of intrapancreatic and neural
inflammation and abdominal neuropathic pain sensation [49].
As of today, further studies investigating other cytokines or
chemokine-receptor duos in CP are still needed.
Looking at the “whole picture” of pancreatic neuropathy,
the recent discoveries in this field point to a collective
contribution of numerous cellular and molecular actors in
the generation of the neuropathic pain in CP: immune cells,
damaged nerves, neurogenesis, activated glia, chemokines,
cytokines, and possibly even several other unidentified
mediators. To our knowledge, despite existence of similar
alterations in some other gastrointestinal (GI) disorders like
Crohn's disease or ulcerous colitis, there is no other GI
disorder than CP and pancreatic cancer where the associ-
ation between these neuropathic alterations and the extent
of neuropathic pain sensation has been this thoroughly
demonstrated. By describing these peripheral nociceptive
mechanisms in CP, we are hereby making an appeal to
consider these as a motivation to investigate similar
alterations in other GI diseases. Nevertheless, it is plausible
to assume that a similar remodeling and pain mechanism
may exist in many other GI disorders, and that pancreatic
neuropathy is in fact a prototype for a more global visceral
neuropathy [29, 51]. The recognition of this possibility
would undoubtedly have major implications for the therapy
of neuropathic pain in CP and other GI diseases.
Central neuropathic and neuroplastic mechanisms:
increased interest in evidence is evidence of increased
interest
The demonstration of the peripheral neural damage in CP
has paved the path to the inauguration of the term
“pancreatic neuropathy” as a novel subtype of peripheral
visceral neuropathy. It is very encouraging to see that the
discovery of these alterations has recently been paralleled
by a number of valuable studies that have tried to verify the
neuropathic pain syndrome in CP at the level of the central
nervous system (CNS). As stated above, in the presence of
peripheral neural damage, nerves become prone to noxious
stimuli from their surroundings and secrete factors that can
further sensitize nociceptors, e.g., neurotransmitters like
glutamate, SP, CGRP, or neurotrophic factors like NGF,
BDNF, and artemin. This continuous sensitization of
peripheral nociceptors results in simultaneous sensitization
of spinal neurons that transmit the peripheral signals to the
brain [52]. This global sensitization is a hallmark of
neuropathic pain syndromes (Fig. 1)[ 52]. As a result of
this sensitization, it is assumed that the cardinal symptoms
of neuropathic pain, i.e., allodynia (pain sensation after
non-noxious stimuli) and hyperalgesia (increased pain
sensation upon a normal pain stimulus), occur [52]. Briefly,
in the presence of continuous nociceptive input, spinal
dorsal horn neurons in the lamina II (substantia gelatinosa)
of the spinal cord that transmit nociceptive signals to brain
start to fire more action potentials due to some crucial
mechanisms: (1) long-term potentiation (LTP) of synaptic
strength via enhanced presynaptic transmitter release or
postsynaptic transmitter effect, (2) changes in membrane
excitability due to lower resting membrane potential or
lower threshold for action potentials, (3) changes in action
potential morphology due to enhanced sodium and depressed
potassiumcurrents, (4) reduced strengthofsynapticinhibition
by inhibitory interneurons, (5) disturbed balance of descend-
ing excitation and inhibition, (6) sprouting of fine primary
afferents, (7) opening of postsynaptic excitatory pathways
from deeper dorsal horn regions (sprouting of Aβ-fibers
towards lamina II), and (8) phenotypic switch in A fibers that
normally transmit only mechanical stimuli (recruitment of
Aβ-fibers to produce SP) [53].
While proving these mechanisms in human CP or even
in animal models represents a true technical challenge,
clinicians have recently made use of keen techniques to at
least assess the symptomatic consequences of such a
hyperexcitability in CP patients. The clinical signs of such
a central hyperexcitability include the following:
1. increase in the “referred pain” area due to convergence
of afferent fibers from different visceral and somatic
organs on the same hyperexcitable spinal (second-
order) neurons [54]
2. “temporal summation,” i.e., repeated stimuli become
increasingly painful in spite of unchanged stimulus
intensity [55]
3. generalized hyperalgesia [55]
In a pioneering study, Dimcevski et al. performed a
multimodal and multi-tissue stimulation in CP patients to see
if there is any increase in the referred pain area, and thus the
sensoryresponseofvisceralandsomaticorgansinCPpatients
[56]. Specifically, they assumed that CP patients would also
harbor a convergence of afferent signals from somatic (skin)
and visceral (esophagus) organs, and that the noxious
stimulation of these organs would provide a picture of the
central hyperexcitability. As hypothesized, they detected a
major difference in the pain response of CP patients and
controls following single and repeated electrical stimulation
156 Langenbecks Arch Surg (2011) 396:151–160in CP patients [56]. This difference reflects the presence of a
key feature of neuropathic pain syndromes in CP, i.e.,
temporal summation [54]. In addition, the investigators
demonstrated a major increase in the referred pain area of
CP patients (30.1 cm
2 in CP vs. 7.7 cm
2 in controls), thereby
proving the two cardinal features of neuropathic pain
syndromes in the context of CP. What remains controversial
are their findings on the “algesia”—status of the patients:
They found that CP patients actually had a hyposensitivity to
mechanical stimulation in their skin, duodenum, and
esophagus [56, 57]. The authors argued that chronic organic
GI diseases like Crohn's disease, esophagitis, and peptic
ulcer have also been shown to bear hypoalgesia to
mechanical stimulation [56–59]. In contrast, Buscher et al.
demonstrated that CP patients show pronounced generalized
deep hyperalgesia even in the presence of opioid therapy
[60, 61]. The precise interpretation of these contradictory
findings is difficult due to the complex pathophysiology of
central pain processing. What is more, it is equally hard to
explain the peripheral hypoalgesia of CP patients as reported
by Dimcevski et al. in the presence of central hyperexcit-
ability and increased referred pain area. However, what looks
like certain is that CNS, especially higher-order centers like
brainstem, has a major modulatory impact on the neuropathic
pain of CP patients. This so-called “descending inhibitory
control” is known to be activated in the presence of
continuous painful stimuli which lead to a reactive suppres-
sion of spinal neuron activity in the dorsal horn (diffuse
noxious inhibitory control/DNIC) [62, 63]. Although it was
suggested that CP patients may rather have a descending
inhibition [9, 56, 57], recent findings do not necessarily
support this assumption. The involvement of a descending
“facilitation” in CP was demonstrated in an elegant study by
Vera-Portocarrero et al.: There, the investigators depleted in a
rat CP model the brainstem cells that are responsible for
descending modulation by a single local injection of
dermorphin-saporin and observed that the maintenance, but
not the expression, of CP-associated abdominal hypersensi-
tivity could be prevented [64]. In another very recent study,
the involvement of such a descending facilitation rather than
an inhibition was verified in CP patients: Upon electrical or
heat stimulation in the rectosigmoid region, CP patients
demonstrated a remarkable remote hyperalgesia when
compared to controls [65]. Therefore, the assumption that
organic GI disorders always exhibit hypoalgesia due to
DNIC [9, 57] cannot be verified in the context of CP where
there are clear indicators of a generalized hyperalgesia.
The increasing interest in discovering evidences for the
neuropathic character of pain in CP can also be well seen in
studies focusing on cerebral pain processing. In one of the
first studies related to this field, the investigators performed
an endoscopic electrical stimulation of esophagus, stomach,
and duodenum of CP patients and simultaneously recorded
event-related brain potentials (ERBPs) via electroencephalo-
gram (EEG) [66]. Remarkably, the early ERBP components
that signify the exogenous brain pain processing had a
significantly lower latency in CP patients than in controls. In
the subsequent analysis, these ERBPs could be localized to
the typical viscero-sensory areas of the cerebral cortex, i.e.,
the bilateral insula, the anterior cingulate gyrus, and the
bilateral secondary somatosensory areas. Very interestingly,
the bilateral insular dipoles drifted more medially and the
cingulate cortex towards more posterior in the CP group
[66], which bears the crucial implication that there is a
reorganization of the cerebral cortex in CP patients. In a
further study, the investigators provided further proof for the
neuropathic character of the pain syndrome in CP by
demonstrating an increased theta wave activity on EEG, a
phenomenon which is typical for neuropathic pain [67]. In
another study, Fregni et al. demonstrated increased glutamate
levels and thus overactivity in the right secondary somato-
sensory cortex as measured by magnetic resonance spectros-
copy [68]. Essentially, there is upcoming firm evidence for a
CNS remodeling and modified CNS activity in CP as a
hallmark of a neuropathic pain syndrome.
Mechanism-based pain treatment in chronic
pancreatitis: where to go from here now?
Seeing the neuropathic character of pain in CP, researchers
started to share their recent experience regarding the usage
of neuropathic pain medications like gabapentin and
tricyclic antidepressant to treat pain in CP [9]. Furthermore,
it has also been suggested that analgesics which act on
κ-type opioid receptors in addition to the μ-type receptors
may bring additional benefit to treat pain in CP [9, 69]: The
κ-receptors are not only upregulated in inflammatory states
but κ-receptor antagonists have also been successful in
treating pain of CP patients [9, 69]. Although randomized
clinical trials testing these neuropathic pain medications are
eagerly awaited, we in our hospital have equally made
effective use of such medications in refractory cases. Still,
looking at the current level of evidence, there is substantial
reason to advocate surgery and especially pancreatic head
resection for pain in CP that is refractory to conservative
medical analgesic treatment [6]. However, what is the
“magic” behind the effectiveness of surgery in the presence
of all these central neuroplastic alterations? In other words,
how can pain due to CP be effectively treated by surgery
despite an already completed remodeling/reorganization
and hyperactivation of the CNS? These questions become
even more intriguing if one carefully ponders over the
recent findings by Fregni et al.: By using non-invasive
repetitive transcranial magnetic stimulation (rTMS) target-
ing the right secondary somatosensory cortex in patients
Langenbecks Arch Surg (2011) 396:151–160 157with CP in a 10-day course, they could achieve a significant
analgesic effect for 3 weeks [70]. In addition to being the
first study to use rTMS in a visceral disorder, this study
should entail offspring studies, which shall verify this effect
in larger cohorts. Whether this costly intervention that
necessitates repeated rTMS sessions and produces only
short-term relief is going to find widespread clinical use
remains unclear. We are convinced that elucidation of the
central neuroplasticity and aberrant pain processing in CP
makes a major contribution to our understanding of visceral
neuropathic pain. However, these fascinating findings
should not distract us very much from the importance of
once again focusing on the peripheral, “original” cause of
this dreadful syndrome. To give an example from a distinct
but still very relevant model of neuropathy, Balasubramanyan
et al. performed a vast analysis of spinal cord neurons where
they compared the electrical properties and excitability of
isolated spinal neurons from normal rats with those of rats
after sciatic chronic constriction injury [71]. This neuropathic
pain model also exhibits noxi-independent pain and abnor-
mal activity in spinal cord neurons in vivo. Very interestingly,
the average intrinsic activity of these neurons in spinal cord
slices was not nearly as high as always assumed. This
observation brought up the key question whether the always
assumed central hyperexcitability isnot necessarily a “reprog-
ramming” of spinal neurons but rather the result of overactive
primary afferents and the continuous release of sensitizers
from the peripheral sensory neurons (peripheral activity-
maintained central sensitization) [52]. As advocated in the
original editorial, the removal of the source of a long-
standing pain (e.g., total hip replacement surgery for
osteoarthritis, release of an entrapped nerve, and childbirth
[52]) may often really be the ultimate solution to chronic
pain even in the presence of potential reprogramming. The
reversibility of this central hyperactivity may be the key for
the success of surgery to treat pain in CP.
Summary and conclusion
Understanding the mechanisms of pain in CP remains a true
challenge. The breathtaking development of pancreatic
surgery in the second half of the twentieth century,
emergence of clinician-scientists, and the growing interest
of basic scientists and pain specialists enabled the accumu-
lation of considerable information regarding the pathogenesis
of this agonizing pain syndrome. Pain in CP should be
analyzed to include the three main perspectives of “peripheral
nociception,”“ peripheral/pancreatic neuropathy and neuro-
plasticity,” and “central neuropathy and neuroplasticity.” It
seems that CP involves sustained sensitization of pancreatic
peripheral nociceptors by neurotransmitters and neurotrophic
factors following neural damage. This peripheral pancreatic
neuropathy leads to intrapancreatic neuroplastic alterations
thatinvolveaprofoundswitchintheautonomicinnervationof
the human pancreas via “neural remodeling.” This peripheral
neuropathy leads to overactivation of spinal sensory second-
order neurons, which in turn assume a hyperexcitable state.
Finally, supraspinal regions in the brainstem and cerebrum
exacerbate this caudal hyperactivation via descending facili-
tation and reorganization to process even more input from the
periphery. Therefore, in the case of this neuropathic pain
syndrome in CP, there is a clear domination of neuropathic
pain mechanisms which, however, in contrast with primary
neuropathic syndromes, show a major dependence from the
ongoingnoxious stimulationfromperipheralnociceptors.The
effectiveness ofsurgicalremovaloftheoriginofthis“nervous
system neuropathy” and the resulting clearance of the
nociceptors that would otherwise continuously transmit
painful stimuli to the CNS represent a crucial peculiarity of
this syndrome. Therefore, due the interdependence of noci-
ception and neuropathy in CP, clinicians may consider pain
due to CP as a “predominantly neuropathic,”“ mixed-type”
pain. We are convinced that the ideal treatment for pain in CP
can only be achieved via careful consideration of this special
mixed mechanism. The fact that pain in CP deserves more
intense investigation than ever probably needs no further
emphasis, especially ifwemay leave up the lastword again to
Hesse: “Der einzige Weg aus der Welt der Schmerzen führt
durch den Schmerz hindurch”/“The only way out of the
world of pain passes straight through pain itself” [72].
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